Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in HCC After Sorafenib
NCT01774344Phase 3Completed
- Sponsor
- Bayer
- Start
- May 2013
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of regorafenib in hepatocellular carcinoma (HCC), sponsored by Bayer. Started May 2013; status: completed.
02
Drugs
regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01774344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01774344.